Claritin Sales Grow For Schering-Plough Despite Zyrtec OTC Competition
This article was originally published in The Tan Sheet
Executive Summary
OTC Claritin sales advanced almost 10 percent in Schering-Plough's fiscal 2008 first quarter despite the "aggressive launch" of Johnson & Johnson's OTC Zyrtec, S-P says
You may also be interested in...
Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows
Johnson & Johnson's OTC sales jumped 27 percent to $1.6 billion in the firm's first earnings period with allergy medication Zyrtec (cetirizine 5 mg) available over the counter, according to J&J
Schering-Plough Cutbacks Underscore Consumer Business Importance
Schering-Plough will look to the diversity of its business with strong OTC and animal health divisions to help weather a major company restructuring that will cut roughly 5,500 jobs and achieve $1.5 billion in cost savings by 2012
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.